BNT162b2 (Pfizer/BioNTech) is a coronavirus disease 2019 (COVID-19) vaccine containing nucleoside-modified messenger RNA encoding the severe acute respiratory syndrome coronavirus 2 spike glycoprotein. Recently, ocular complications of mRNA vaccines have been reported increasingly frequently. However, immunological adverse events due to mRNA vaccines in real-world settings are not fully known. We herein report the novel development of sarcoidosis manifested as uveitis, bilateral hilar lymphadenopathy, angiotensin-converting enzyme elevation, and epithelioid and giant cell granuloma formation in the lung soon after the first BNT162b2 injection and review the current literature, including three reported cases of sarcoid-like reaction following COVID-19 vaccination.
Novel development of sarcoidosis manifested as uveitis, bilateral hilar lymphadenopathy, angiotensin-converting enzyme elevation, and epithelioid and giant cell granuloma formation in the lung soon after the first #Pfizer BNT162b2 injection
https://t.co/ja4rVG1vdk
A Novel Development of Sarcoidosis Following COVID-19 Vaccination and a Literature Review https://t.co/p4fGSek7Rn
鹿先生 サルコイドーシス(おできが内蔵にできちゃう病気)、視力障害
●ワクチン後症候群の症例報告論文(東北大学)
https://t.co/fs0uifW2hk
A Novel Development of Sarcoidosis Following COVID-19
Vaccination and a Literature Review
https://t.co/rGsYbEpVTg